Despite the similar positive prevalence between the KRAS and GNAS mutations (70–80%) in the resected IPMN specimens, a much lower prevalence of KRAS mutation than that of GNAS was detected in cfDNA. The gene discussed is GNAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.